Compare DexCom, Inc. (DXCM) vs Rigetti Computing Inc (RGTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Rigetti Computing Inc — how do they compare? DexCom, Inc. trades at $77.86 (market cap $28.06B), while Rigetti Computing Inc trades at $14.49 (market cap $5.07B). The key difference: DexCom, Inc. is far larger — about 5.5× Rigetti Computing Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Rigetti Computing Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | RGTI | |
|---|---|---|
Market Cap | $28.06B | $5.07B |
Sector | Health | Technology |
52-Week High | $89.53 | $56.34 |
52-Week Low | $54.84 | $12.90 |
Enterprise Value | $27.03B | $4.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Rigetti Computing (RGTI) trades at $14.72, down 8.63% with bearish technical signals. The company shows negative profitability with -2,253.59% net margin and -$216.21M net loss in 2025, though quarterly EPS has beaten expectations. Analyst sentiment remains strong with 85.71% buy ratings and $32.67 consensus target. Recent news highlights quantum computing sector volatility and Rigetti's infrastructure advancements amid ongoing cash burn.
The stock offers high-risk growth potential in quantum computing with significant analyst upside but faces substantial execution risks. Key challenges include persistent losses, cash burn of $22.82M in 2025, and intense sector competition. Investment suitability depends on risk tolerance for pre-revenue technology ventures with long commercialization timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →
